306 related articles for article (PubMed ID: 19702527)
1. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
[TBL] [Abstract][Full Text] [Related]
2. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.
Wang H; Tompkins LM
Curr Drug Metab; 2008 Sep; 9(7):598-610. PubMed ID: 18781911
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2B6: function, genetics, and clinical relevance.
Turpeinen M; Zanger UM
Drug Metabol Drug Interact; 2012; 27(4):185-97. PubMed ID: 23152403
[TBL] [Abstract][Full Text] [Related]
4. Structure, function, regulation and polymorphism of human cytochrome P450 2A6.
Di YM; Chow VD; Yang LP; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):754-80. PubMed ID: 19702528
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
Zanger UM; Klein K; Saussele T; Blievernicht J; Hofmann MH; Schwab M
Pharmacogenomics; 2007 Jul; 8(7):743-59. PubMed ID: 17638512
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
[TBL] [Abstract][Full Text] [Related]
9. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.
Ilic K; Hawke RL; Thirumaran RK; Schuetz EG; Hull JH; Kashuba AD; Stewart PW; Lindley CM; Chen ML
Drug Metab Dispos; 2013 Mar; 41(3):575-81. PubMed ID: 23238783
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
[TBL] [Abstract][Full Text] [Related]
11. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
[TBL] [Abstract][Full Text] [Related]
12. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers.
Faucette SR; Zhang TC; Moore R; Sueyoshi T; Omiecinski CJ; LeCluyse EL; Negishi M; Wang H
J Pharmacol Exp Ther; 2007 Jan; 320(1):72-80. PubMed ID: 17041008
[TBL] [Abstract][Full Text] [Related]
13. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.
Miksys S; Lerman C; Shields PG; Mash DC; Tyndale RF
Neuropharmacology; 2003 Jul; 45(1):122-32. PubMed ID: 12814665
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
Robertson SM; Maldarelli F; Natarajan V; Formentini E; Alfaro RM; Penzak SR
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):513-9. PubMed ID: 18989234
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of CYP2B6 cDNA in cynomolgus macaques (Macaca fascicularis).
Uno Y; Matsuno K; Nakamura C; Utoh M; Yamazaki H
J Vet Med Sci; 2009 Dec; 71(12):1653-6. PubMed ID: 20046035
[TBL] [Abstract][Full Text] [Related]
16. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.
Lee AM; Jepson C; Hoffmann E; Epstein L; Hawk LW; Lerman C; Tyndale RF
Biol Psychiatry; 2007 Sep; 62(6):635-41. PubMed ID: 17223085
[TBL] [Abstract][Full Text] [Related]
17. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Kirchheiner J; Klein C; Meineke I; Sasse J; Zanger UM; Mürdter TE; Roots I; Brockmöller J
Pharmacogenetics; 2003 Oct; 13(10):619-26. PubMed ID: 14515060
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.
Penzak SR; Kabuye G; Mugyenyi P; Mbamanya F; Natarajan V; Alfaro RM; Kityo C; Formentini E; Masur H
HIV Med; 2007 Mar; 8(2):86-91. PubMed ID: 17352764
[TBL] [Abstract][Full Text] [Related]
19. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046
[TBL] [Abstract][Full Text] [Related]
20. [Cyclophosphamide and CYP2B6].
Torimoto Y; Kohgo Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1090-3. PubMed ID: 18633247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
